Bring the power of MR imaging into your urology practice to support you at every step of a prostate cancer patient’s journey. This allows you to confidently deliver the precise care your patients deserve. Our prostate cancer care solutions features DynaCAD Prostate for advanced visualization, analysis of multi-parametric MR imaging and UroNav for live MR/ultrasound fusion-guided biopsy and therapy procedures.
30% improvement in high-risk prostate cancer diagnosis can be achieved using fusion biopsy versus standard biopsy. Additionally, there can be experienced a 13.3% reduction in pathological upgrading to clinically significant prostate cancer with targeted and systematic biopsies versus systematic biopsies alone.5
DynaCAD Prostate offers direct image transfer from your MR scanner for time and workflow efficiency. Analysis and reporting of mpMRI studies are made easy thanks to its robust, automatic post‑processing tools and the ability to display results in customized hanging protocols. At case completion, key images, statistical data and prostate PI-RADS® reports2 can be automatically transferred to PACS for archiving. DynaCAD Prostate helps you enhance confidence and productivity for precise patient care.
UroNav is designed to support you with image guidance during prostate biopsies and focal therapy procedures. It fuses diagnostic MR images of the prostate with live ultrasound images for guided procedures in real time. You get clear delineation of the prostate and suspicious lesions, as well as clear visualization of the needle path. Reach 10% increase in prostate cancers identified with combined targeted and systematic biopsy compared to systematic biopsy alone.4
Products not available for sale in all countries. Please contact your sales representative to ascertain availability in your country. Results are specific to the institution where they were obtained and may not reflect the results achievable at other institutions.
[1] DynaCAD Prostate is a module of the DynaCAD product.
[2] PI-RADS® is a registered trademark of The American College of Radiology.
[3] U.S. News and World Report: 2024 Best Hospitals Ranking (Urology).
[4] Siddiqui MM, et al. Comparison of MR/ultrasound fusion–guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390-397.
[5] Ahdoot M, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. NEMJ. 2020382:917–928. doi: 10.1056/NEJMoa1910038
You are about to visit a Philips global content page
Continue